Phase 3 · NCT06297603
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor
Registry record
Trial details
- Trial
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- ClinicalTrials.gov ID
- NCT06297603
- Indication
- Type 2 Diabetes
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 320
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 76 sites · Argentina, Brazil, Israel, Mexico, Puerto Rico, United Kingdom, United States
- Study start
- 15 Mar 2024
- Primary completion
- 1 Oct 2026
- Study completion
- 1 Nov 2026
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 20 Jul 2026
Endpoints
Primary
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Secondary
Percentage of Participants Achieving HbA1c <7.0%; Percentage of Participants Achieving HbA1c ≤6.5%; Change from Baseline in Fasting Serum Glucose; Percentage of Time Continuous Glucose Monitoring (CGM) Glucose Values are Between 70 and 180 mg/dL; Percent Change from Baseline in Body Weight; Change from Baseline in Body Weight; Percentage of Participants Achieving Weight Reduction of ≥5%; Percentage of Participants Achieving Weight Reduction of ≥10%; Percentage of Participants Achieving Weight Reduction of ≥15%; Percentage of Participants Achieving HbA1c ≤6.5% and ≥10% Weight Reduction; Percent Change from Baseline in Non-HDL Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure (SBP)